NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
Myeloma X Relapse
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Multiple Myeloma RRMM - Myeloma X Relapse
Time Frame: April 16, 2008, and Nov 19, 2012
Myeloma X Relapse
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Sponsor
Leeds Cancer Centre at St. James's University Hospital
Information provided by
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00747877
Official Title: Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.
First Posted: September 5, 2008
Click here for details on ClinicalTrials.gov
Drug: cyclophosphamide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Lancet Oncol;2014
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Lancet Haematol;2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
Biol Blood Marrow Transplant;2016
Click here for details
https://pubmed.ncbi.nlm.nih.gov/26827659/
Location
United Kingdom